Ligand Pharmaceuticals (NASDAQ:LGND) posted its earnings results on Thursday. The biotechnology company reported $1.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.48, Bloomberg Earnings reports. Ligand Pharmaceuticals had a return on equity of 25.57% and a net margin of 57.00%. The business had revenue of $59.59 million during the quarter, compared to analysts’ expectations of $52.58 million. During the same period in the previous year, the business earned $1.31 earnings per share. The firm’s revenue was up 18.1% on a year-over-year basis. Ligand Pharmaceuticals updated its FY 2019 guidance to $6.05-6.05 EPS and its FY19 guidance to ~$6.05 EPS.
LGND opened at $114.48 on Friday. Ligand Pharmaceuticals has a 12-month low of $98.56 and a 12-month high of $278.62. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.20 and a quick ratio of 2.19. The stock has a market capitalization of $2.43 billion, a PE ratio of 18.23, a PEG ratio of 1.19 and a beta of 1.40.
Several equities analysts recently commented on the company. TheStreet cut Ligand Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Wednesday, January 2nd. HC Wainwright set a $280.00 target price on Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 29th. Zacks Investment Research cut Ligand Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. BidaskClub cut Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 12th. Finally, ValuEngine upgraded Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $238.00.
ILLEGAL ACTIVITY NOTICE: “Ligand Pharmaceuticals (LGND) Issues Quarterly Earnings Results, Beats Estimates By $0.48 EPS” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/4139216/ligand-pharmaceuticals-lgnd-issues-quarterly-earnings-results-beats-estimates-by-0-48-eps.html.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Featured Story: Diversification For Individual Investors
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.